Walter Reed Army Institute of Research

With COVID-19, coronaviruses have been the focus of recent drug development efforts, but their tendency to mutate has made them a difficult beast to tame. As a precursor to the development of a pan-co

FDA should consider allowing sponsors of treatments targeting a single species of bacteria to select from, and possibly combine, studies from a menu of options to evaluate safety and effectiveness, FD

IN VITRO DIAGNOSTICS Mergers & Acquisitions PDI Inc. Interpace Diagnostics LLC RedPath Integrated Pathology Inc. PDI Inc. acquired molecular diagnostics company RedPath Integrated Pathology Inc.

In Vitro Diagnostics Alliances